Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants should have successfully completed treatment in the M16-046 study, without meeting any permanent discontinuation criteria.
Participant is judged to be in general good health (other than AD) as determined by the Principal Investigator and remains eligible as per the criteria for the study M16-046 to continue treatment in the long term extension study.
You may not be if
Requirement of prohibited medications during the study treatment or would interfere with appropriate assessment of atopic dermatitis lesions.
Female participant who is pregnant, breastfeeding, or considering pregnancy during the study.
Clareo Health | Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
